The purpose of the present study is to demonstrate the higher efficacy of Foster® NEXThaler®
100/6 extra fine (two inhalations b.i.d.) versus Seretide® Accuhaler® 250/50 (one inhalation
b.i.d.), in terms of pulmonary function (change from baseline to the end of treatment in
post-dose peripheral airway resistance) in patients with asthma.
Phase:
Phase 3
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Treatments:
Beclomethasone Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Formoterol Fumarate Salmeterol Xinafoate